0633 Benign Skin Lesion Removal - Aetna Better Health
Transcript of 0633 Benign Skin Lesion Removal - Aetna Better Health
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 1 of 14
(https://www.aetna.com/)
Benign Skin Lesion Removal
Clinical Policy Bulletins Medical Clinical Policy Bulletins
Policy History
Last
Review
09/11/2019
Effective: 08/02/200
Next Review:
06/26/2020
Review History
Definitions
Additional Information
Number: 0633
Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB.
Aetna considers removal of acquired or small (less than 1.5 cm) congenital nevi
(moles), cutaneous and subcutaneous neurofibromas, dermatofibromas,
acrochordon (skin tags), pilomatrixomata (slow-growing hard mass underneath the
skin that arises from hair follicle matrix cells), sebaceous cysts (pilar and
epidermoid cysts), seborrheic keratoses (also known as basal cell papillomas,
senile warts or brown warts), or other benign skin lesions, or needle hyfrecation for
sebaceous hyperplasia, medically necessary if any of the following criteria is met:
Biopsy suggests or is indicative of pre-malignancy (e.g., dysplasia) or
malignancy; or
Due to its anatomic location, the lesion has been subject to recurrent
trauma/irritation (eg, bra line, waist band, etc.); or
Lesion appears to be pre-malignant (e.g., actinic keratoses
(see CPB 0567 - Actinic Keratoses Treatment (../500_599/0567.html)),
Bowen's disease, dysplastic lesions, dysplastic nevus syndrome, large
congenital melanocytic nevi, lentigo maligna, or leukoplakia) or malignant* (due
to coloration, change in appearance or size, etc. (see note below) especially in
a person with personal or family history of melanoma); or
Skin lesions are causing symptoms (e.g., bleeding, burning, intense itching, or
irritation); or
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 2 of 14
The lesion has evidence of inflammation (e.g., edema, erythema, or purulence);
or
The lesion is infectious (e.g., warts (verruca vulgaris)); or
The lesion restricts vision or obstructs a body orifice.
In the absence of any of the above indications, removal of seborrheic keratoses,
sebaceous cysts, small nevi (moles), dermatofibromas, pilomatrixoma, or other
benign skin lesions, or needle hyfrecation for sebaceous hyperplasia, is considered
cosmetic.
* Note: Clinical suspicion of malignancy, is indicated by any of the following:
Asymmetry – one half of the mole or lesion does not match the other;
Border – the edges of a mole or lesion are irregular, ragged, blurred;
Color – the color is not the same all over and may include shades of brown
or black or sometimes have patches of pink, red, white or blue;
Diameter – the mole or lesion is larger than six millimeters across (about ¼
inch or the size of a pencil eraser); or
Evolving – the mole is changing in size (enlarging), shape or color.
Background
A skin lesion is a nonspecific term that refers to any change in the skin surface; it
may be benign, malignant or premalignant. Skin lesions may have color (pigment),
be raised, flat, large, small, fluid filled or exhibit other characteristics. Common
examples of benign skin lesions may include moles (nevi), sebaceous cysts,
seborrheic keratoses, skin tags (acrochordon), callouses, corns or warts.
The treatment of benign skin lesions consists of destruction or removal by any of a
wide variety of techniques. The removal of a skin lesion can range from a simple
biopsy, scraping or shaving of the lesion, to a radical excision that may heal on its
own, be closed with sutures (stitches) or require reconstructive techniques involving
skin grafts or flaps. Laser, cautery or liquid nitrogen may also be used to remove
benign skin lesions. When it is uncertain as to whether or not a lesion is cancerous,
excision and laboratory (microscopic) examination is usually necessary.
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 3 of 14
Seborrheic keratoses are non-cancerous growths of the outer layer of skin. They
are usually brown, but can vary in color from beige to black, and vary in size from a
fraction of an inch to more than an inch in diameter. They may occur singly or in
clusters on the surface of the skin. They typically has a wart-like texture with a waxy
appearance, and have the appearance of being glued or stuck on to skin.
Seborrheic keratoses are most often found on the chest or back, although, they can
also be found almost anywhere on the body. These become more common with
age, and most elderly patients develop one or more of these lesions. Seborrheic
keratoses can get irritated by clothing rubbing against them, and their removal may
be medically necessary if they itch, get irritated, or bleed easily. Although
seborrheic keratoses are non-cancerous, they may be difficult to distinguish from
skin cancer if they turn black. Seborrheic keratoses may be removed by
cryosurgery, curettage, or electrosurgery.
Acquired nevi (moles) can appear anywhere on the skin. They are usually brown in
color, but can be skin colored or pink, light tan to brown, or blue-black. Moles may
be flat or raised and can be various sizes and shapes. Most appear during the first
20 years of a person's life, although some may not appear until later in life. Sun
exposure increases the number of moles. The majority of moles are benign.
However, moles that raise suspicion of malignancy are those that change in size,
shape or color, and those that bleed, itch, or become painful. Atypical moles
(dysplastic nevi) have an increased risk of developing into melanoma. Atypical
moles are larger than average (greater than 6 mm) and irregular in shape. They
tend to have uneven color with dark brown centers and lighter, sometimes reddish,
uneven borders or black dots at edge. The most common methods of removal
include shaving and excision.
Congenital melanocytic nevi occur in approximately 1 % of newborns and are
usually classified according to their size. Giant congenital melanocytic nevi are
most simply defined as melanocytic nevi that are greater than 20 cm in largest
dimension; whereas small congenital nevi are defined as melanocytic nevi less than
1.5 cm in largest dimension. Giant congenital melanocytic nevi are associated with
an increased risk of the development of melanoma, and are therefore surgically
removed. However, small congenital nevi do not need to be removed as the risk of
malignant transformation is thought to be small or none. The management of
intermediate sized congenital nevi is controversial, as the risk of malignant
transformation and the lifetime melanoma risk in patients with intermediate sized
congenital nevi is not known.
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 4 of 14
A sebaceous (keratinous) cyst is a slow-growing, benign cyst that contains
follicular, keratinous, and sebaceous material. The sebaceous cyst is firm,
globular, movable, and non-tender. These cysts seldom cause discomfort unless
the cyst ruptures or becomes infected. Ranging in size, sebaceous cysts are
usually found on the scalp, face, ears, and genitals. They are formed when the
release of sebum from the sebaceous glands in the skin is blocked. Unless they
become infected and painful or large, sebaceous cysts do not require medical
attention or treatment, and usually go away on their own. Infected cysts can be
incised and drained, or the entire cyst may be surgically removed.
A skin tag (arochordon) is a benign, soft, moveable, skin-colored growth that hangs
from the surface of the skin on a thin piece of tissue called a stalk. The prevalence
of skin tags increases with age. They appear most often in skin folds of the neck,
armpits, trunk, beneath the breasts or in the genital region. They are painless, but
may become painful if thrombosed or if irritated. They may become irritated if they
occur in an area where clothing or jewelry rubs against them. Skin tags may be
removed by excision, cryosurgery, or electrosurgery.
Actinic keratoses are the most common type of premalignant skin lesions, occurring
in sun-exposed areas that may give rise to squamous cell carcinomas. They are
thought to be caused by years of exposure to the sun. The lesions are scaly
sandpaper-like patches, varying in color from skin-colored to reddish-brown or
yellowish-black. Lesions may be single or multiple. They are usually painless but
may be slightly tender. Actinic keratoses are discussed
in CPB 0567 - Actinic Keratoses Treatment (../500_599/0567.html).
Bowen's disease (squamous cell carcinoma in situ) is a pre-malignant lesion, often
due to arsenic exposure, that may give rise to squamous cell carcinoma. Lesions
predominantly affect the elderly, and consist of persistent, erythematous, scaly
plaques with well-defined margins. Treatment options include excision,
cryotherapy, curettage and cautery, and topical 5-fluorouracil.
Lentigo maligna (Hutchinson's Freckle) is a pre-malignant lesion that may give rise
to lentigo maligna melanoma. These lesions are pigmented macules, often greater
than 1 cm in diameter with an irregular border, occurring mainly on sun-exposed
areas. Lesions characteristically have brown, black, red, and white areas and
become more irregularly pigmented over time. Risk of conversion to melanoma by
age 75 is estimated at 1 to 2 %. Patients should undergo regular follow-up
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 5 of 14
examinations for signs of conversion to melanoma. Because conversion to
melanoma is usually relatively slow, the decision to excise lentigo maligna should
be based on several factors, including the size and location of the lesion, which
determines the complexity of the procedure required, and the patient's life
expectancy and comorbidities.
A hemangioma is a benign tumor consisting chiefly of dilated or newly formed blood
vessels. A port wine stain is a reddish purple superficial hemangioma of the skin
commonly occurring as a birthmark.
Pirouzmanesh and colleagues (2003) noted that pilomatrixoma, also known as
calcifying epithelioma of Malherbe, is a benign skin neoplasm that arises from hair
follicle matrix cells. Pilomatrixoma is a common skin neoplasm in the pediatric
population that is often mis-diagnosed as other skin conditions. This study
reviewed an 11-year experience at a tertiary children's hospital, examining the
cause, clinical and histopathological presentation, management, and treatment
outcomes of pilomatrixoma. A review of the pathology database at Children's
Hospital Los Angeles revealed 346 pilomatrixomas excised from 336 patients
between 1991 and 2001. The hospital charts, pathology records, and plastic
surgery clinic charts were reviewed with respect to variables such as sex, age at
the time of presentation, clinical and histopathological presentation, pre-operative
diagnosis, management, recurrence, and treatment outcome. The main presenting
symptom was a hard, subcutaneous, slowly growing mass. The pre-operative
diagnosis was accurate and consistent with the pathological diagnosis of
pilomatrixoma in only 100 cases (28.9 %). This entity should be considered with
other benign or malignant conditions in the clinical differential diagnosis of solitary
firm skin nodules, especially those on the head, neck, or upper limbs. The
diagnosis can generally be made with a clinical examination. Imaging studies are
not required unless symptoms or the location of the lesion warrants such diagnostic
assessments. The treatment of choice is surgical excision, and the recurrence rate
is low.
Roche et al (2010) stated that a pilomatricoma, also known as pilomatrixoma or
calcifying epithelioma of Malherbe, is a benign skin tumor arising from the hair
follicle matrix. This tumor is common in children and young adults, especially in the
head and neck region. However, pilomatricomas are frequently mis-diagnosed or
not recognized. The history is typical of a slowly enlarging mass, irregularly
contoured; it is fixed to the skin but slides freely over the, underlying tissues, often
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 6 of 14
with a discoloration that varies from red to purple-bluish. Ultrasound examination,
magnetic resonance imaging, and fine-needle aspiration can be helpful if the
diagnosis is uncertain. Spontaneous regression has never been observed and
malignant degeneration is very rare. Surgical excision with clear margins is the
treatment of choice, otherwise recurrence may occur due to incomplete resection.
Guinot-Moya et al (2011) determined the incidence and clinical features of patients
diagnosed with pilomatrixoma. A retrospective analysis was made of 205 cases of
pilomatrixoma diagnosed according to clinical and histological criteria, with an
evaluation of the incidence, patient age at presentation, gender, lesion location and
size, single or multiple presentation, differential diagnosis, histopathological and
clinical findings and relapses. Pilomatrixoma was seen to account for 1.04 % of all
benign skin lesions. It tended to present in pediatric patients -- almost 50 %
corresponding to individuals under 20 years of age -- with a slight male predilection
(107/98). Approximately 75 % of all cases presented as single lesions measuring
less than 15 mm in diameter. Multiple presentations were seen in 2.43 % of cases.
The most frequent locations were the head and orofacial zones (particularly the
parotid region), with over 50 % of all cases, followed by the upper (23.9 %) and
lower limbs (12.7 %). Only 1 relapse was documented following simple lesion
excision. The authors concluded that the frequency of pilomatrixomas was 1.04 %
of all benign skin lesions -- the lesions being predominantly located in the
maxillofacial area. Due to the benign features of this disorder, simple removal of
the lesion is considered to be the treatment of choice, and is associated with a very
low relapse rate.
Porokeratosis is a disorder of keratinization characterized by one or more atrophic
macules or patches surrounded by a distinctive hyperkeratotic ridge-like border
called a cornoid lamella (Spencer, 2011; Spencer, 2012). The coronoid lamella is a
a thin column of closely stacked, parakeratotic cells extending through the stratum
corneum with a thin or absent granular layer. Multiple clinical variants of
porokeratosis exist. The most commonly described variants include: disseminated
superficial actinic porokeratosis (DSAP), disseminated superficial porokeratosis
(DSP), classic porokeratosis of Mibelli, linear porokeratosis, porokeratosis plantaris
palmaris et disseminata, and punctate porokeratosis. The diagnosis of
porokeratosis often can be made based solely on clinical examination (Spencer,
2011; Spencer, 2012). The clinical appearance of an atrophic macule or patch with
a well-defined, raised, hyperkeratotic ridge suggests this disorder. Biopsies are
typically performed when the appearance of the lesion is not classic or when there
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 7 of 14
is concern for malignant transformation. Malignant transformation has occurred in
patients with all major variants of porokeratosis with the exception of punctate
porokeratosis. It is estimated to occur in 7.5 to 11 percent of patients, with an
average period to cancer onset of 36 years (Spencer, 2011; Spencer, 2012). Linear
porokeratosis and giant porokeratosis (a manifestation of porokeratosis of Mibelli)
are the variants most susceptible to malignant transformation, while this occurrence
in DSAP is rare. Although removal of lesions via surgical or destructive methods is
an option for the prevention of malignant transformation in lesions of porokeratosis,
the need to do so is questionable (Spencer, 2011; Spencer, 2012). Factors such as
the estimated risk for malignancy for specific lesion types and the risk for significant
cosmetic or functional defects following removal must be considered. The removal
of the lesions with the greatest risk for malignancy (linear porokeratosis or large
porokeratosis of Mibelli) often would result in an unfavorable amount of scarring.
Moreover, the large number of lesions and low risk for malignancy in individual
lesions of DSAP or DSP suggest that the benefit of lesion removal for the
prevention of malignancy in these variants is likely to be minima (Spencer, 2011;
Spencer, 2012). The ability to clinically follow lesions of porokeratosis for signs or
symptoms of malignancy and the high likelihood of successful treatment of
malignancy once it develops support clinical surveillance as an acceptable method
of management, and thus, most patients with porokeratosis are followed clinically
(Spencer, 2011; Spencer, 2012). Lesions suggestive of malignancy require
excision, whereby micrographic surgery offers a precise way of separating the
tumor from its porokeratotic background (Sertznig, et al., 2012). Although
nonexcisional destructive methods (.g., laser, cryotherapy) has been used to
remove isolated porokeratosis lesions, there are no studies showing the value of
prophylactic non-excisional surgical treatment in reducing the incidence of
malignancy in cases of porokeratosis (Sertznig, et al., 2012). If the decision is made
to excise or destroy a lesion for prophylactic purposes, doing so in an urgent
manner is not necessary, as the period between lesion development and
malignancy often spans decades. After removal, clinical follow-up still should be
performed yearly to evaluate these patients for the development of new or recurrent
lesions (Spencer, 2011; Spencer, 2012).
Cutaneous and Subcutaneous Neurofibromas
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 8 of 14
An UpToDate review on “Neurofibromatosis type 1 (NF1): Management and
prognosis” (Korf, 2015) states that “Cutaneous and subcutaneous neurofibromas
are not removed unless there is a specific need for removal (e.g., pain, bleeding,
interference with function, disfigurement). Referral to dermatology is advised for
patients with severe pruritus”.
Cutaneous Skeletal Hypophosphatemia Syndrome
Ovejero and colleagues (2016) stated that cutaneous skeletal hypophosphatemia
syndrome (CSHS), caused by somatic RAS mutations, features excess fibroblast
growth factor-23 (FGF23) and skeletal dysplasia. In this study, records from 56
individuals were reviewed and demonstrated fractures, scoliosis, and non-
congenital hypophosphatemia that in some cases were resolved. Phosphate and
calcitriol, but not skin lesion removal, were effective at controlling
hypophosphatemia. No skeletal malignancies were found; 5 CSHS subjects
underwent prospective data collection at clinical research centers. A review of the
literature identified 45 reports that included a total of 51 additional patients, in whom
the findings were compatible with CSHS. Data on nevi subtypes, bone histology,
mineral and skeletal disorders, abnormalities in other tissues, and response to
treatment of hypophosphatemia were analyzed. Fractures, limb deformities, and
scoliosis affected most CSHS subjects. Hypophosphatemia was not present at
birth. Histology revealed severe osteomalacia but no other abnormalities. Skeletal
dysplasia was reported in all anatomical compartments, though less frequently in
the spine; there was no clear correlation between the location of nevi and the
skeletal lesions. Phosphate and calcitriol supplementation was the most effective
therapy for rickets. Convincing data that nevi removal improved blood phosphate
levels was lacking. An age-dependent improvement in mineral abnormalities was
observed. A spectrum of extra-osseous/extra-cutaneous manifestations that
included both benign and malignant neoplasms was present in many subjects,
though osteosarcoma remains un-reported.
Needle Hyfrecation for Sebaceous Hyperplasia
Hyfrecation refers to the use of a device that is designed for use in electro-surgery
on conscious patients, usually in the office-setting. A hyfrecator is used to destroy
tissue directly, and to stop bleeding during minor surgery. It works by emitting low-
power, high-frequency, high-voltage AC electrical pulses, via an electrode mounted
on a hand-piece, directly to the affected area of the body.
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 9 of 14
Bader and Scarborough (2010) noted that sebaceous hyperplasia is a common,
benign proliferation of sebaceous glands occurring predominantly on the face.
Clinically, there is 1 or several, 2- to 4-mm yellowish papules, often with a central
umbilication representing the site of a ductal opening. Sebaceous hyperplasia has
been found to occur with an increased frequency in patients receiving hemodialysis
or immunosuppressive therapy, especially after kidney transplantation. Most often
these lesions represent little more than a cosmetic concern, although they may be
confused clinically with basal cell carcinoma.
An UpToDate review on “Cutaneous adnexal tumors” (North et al, 2019) states that
“Sebaceous hyperplasia is a relatively common lesion resulting from the
enlargement of normal sebaceous glands. Sebaceous hyperplasia is not a true
tumor, but shares clinical and histopathologic features with sebaceous adenoma. It
typically presents as 2- to 6-mm umbilicated, skin-colored to yellowish or brownish
papules on the forehead, nose, and cheeks of older individuals. Rarely, lesions can
occur on the areola, genitalia, and anterior chest, sometimes in a linear
configuration ("juxtaclavicular beaded lines"). Sebaceous hyperplasia has been
reported in 15 to 30 % of transplant patients treated with cyclosporine. The so-
called premature sebaceous hyperplasia presents with multiple discrete or plaque-
like lesions in children and adolescents and is considered a hamartomatous lesion
related to nevus sebaceous … Treatment is for cosmetic reasons and includes
electrosurgery, cryosurgery, shave removal, dermabrasion, laser therapy, and oral
isotretinoin”.
Appendix
Pre-Malignant Skin Lesions (Not an all-inclusive list)
Actinic keratosis
Lentigo maligna
Leukoplakia
Squamous cell carcinoma in-situ (Bowen's disease)
Skin Lesions That Do Not Qualify as Pre-Malignant (Not an all-inclusive list)
Acrochordons (skin tags)
Cherry angioma
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 10 of 14
Dermatofibroma
Hemangioma (superficial or deep)
Neurofibroma
Nevus flammeus (port-wine stain)
Nevus simplex
Pyogenic granuloma
Seborrheic keratosis
Telangiectasia
Verruca vulgaris (warts).
CPT Codes / HCPCS Codes / ICD-10 Codes
Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":
Pre-Malignant Lesions:
CPT codes covered if selection criteria are met:
ICD-10 codes covered if selection criteria are met:
K13.21
L57.0
Benign Lesions:
CPT codes covered if selection criteria are met:
11200 - 11201 Removal of skin tags, multiple fibrocutaneous tags, any area
11300 - 11313 Shaving of epidermal or dermal lesions
11400 - 11446 Excision, benign lesions
17110 - 17111 Destruction, (eg, laser surgery, electrosurgery, cryosurgery,
chemosurgery, surgical curettement), of benign lesions other than skin
tags or cutaneous vascular lesions
54050 - 54065 Destruction of lesion(s), penis (eg, condyloma, papilloma, molluscum
contagiosum, herpetic vesicle)
56501 - 56515 Destruction of lesion(s), vulva
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 11 of 14
Code Code Description
57061 - 57065 Destruction of vaginal lesion(s)
64788 Excision of neurofibroma or neurolemmoma; cutaneous nerve
64790 Excision of neurofibroma or neurolemmoma; major peripheral nerve
64792 Excision of neurofibroma or neurolemmoma; extensive (including
malignant type)
64788 Excision of neurofibroma or neurolemmoma; cutaneous nerve
64790 Excision of neurofibroma or neurolemmoma; major peripheral nerve
64792 Excision of neurofibroma or neurolemmoma; extensive (including
malignant type)
CPT codes not covered for indications listed in the CPB:
0419T Destruction neurofibroma, extensive, (cutaneous, dermal extending into
subcutaneous); face, head and neck, greater than 50 neurofibroma
0420T Destruction neurofibroma, extensive, (cutaneous, dermal extending into
subcutaneous); trunk and extremities, extensive, greater than 100
neurofibroma
ICD-10 codes covered if selection criteria are met:
A63.0 Anogenital (venereal) warts
B07.0 - B07.9 Viral warts [* note - report 17110-17111 per AMA CPT guidelines]
B08.1 Molluscum contagiosum
D04.0 - D04.9 Carcinoma in situ of skin [Bowen's disease, lentigo maligna]
D17.0 - D17.39 Benign lipomatous neoplasm of skin and subcutaneous tissue
D18.00 - D18.09 Hemangioma [superficial ordeep]
D22.0 - D22.9 Melanocytic nevi
D23.0 - D23.9 Other benign neoplasm of skin
D36.10 - D36.9 Benign neoplasm of other and unspecified sites [neurofibroma]
D48.5 Neoplasm of uncertain behavior of skin [dysplastic nevus syndrome]
I78.1 Nevus, non-neoplastic [nevus simplex, telangiectasia, cherry angioma]
L72.0 Epidermal cyst
L72.3 Sebaceous cyst
L82.0 - L82.1 Seborrheic keratosis
L91.0 - L91.9 Hypetrophic scar [acrochordons, skin tags]
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 12 of 14
L98.0
Q82.5
ICD-10 codes not covered for indications listed in the CPB:
L73.8
The above policy is based on the following references:
1. American Academy of Dermatology (AAD). Seborrheic keratoses. Patient
Information. Schaumburg, IL: AAD; 1997.
2. American Academy of Dermatology (AAD). Moles. Patient Information.
Schaumburg, IL: AAD; 1987.
3. Beers MH, Berkow R, eds. Disorders of hair follicles and sebaceous glands:
Keratinous cyst. In: The Merck Manual of Diagnosis and Therapy. 17th ed.
Sec. 10, Ch. 116. White House Station, NJ: Merck & Co.; 2002.
4. Zuber TJ. Minimal excision technique for epidermoid (sebaceous) cysts. Am
Fam Physician. 2002;65(7):1409-1412, 1417-1418, 1420.
5. Berg P, Lindelof B. Congenital nevocytic nevi: Follow-up of a Swedish birth
register sample regarding etiologic factors, discomfort, and removal rate.
Pediatr Dermatol. 2002;19(4):293-297.
6. Tannous ZS, Mihm MC Jr, Sober AJ, Duncan LM. Congenital melanocytic
nevi: clinical and histopathologic features, risk of melanoma, and clinical
management. J Am Acad Dermatol. 2005;52(2):197-203.
7. Beers MH, Jones TV, Berkwitz M, et al., eds. Skin cancers: Premalignant
lesions. In: The Merck Manual of Geriatrics. 3rd ed. Sec. 15, Ch. 125. White
House Station, NJ: Merck & Co.; 2000.
8. Danielson-Cohen A, Lin SJ, Hughes CA, et al. Head and neck pilomatrixoma
in children. Arch Otolaryngol Head Neck Surg. 2001;127(12):1481-1483.
9. Pirouzmanesh A, Reinisch JF, Gonzalez-Gomez I. Pilomatrixoma: A review of
346 cases. Plast Reconstr Surg. 2003;112(7):1784-1789.
10. Roche NA, Monstrey SJ, Matton GE. Pilomatricoma in children: Common but
often misdiagnosed. Acta Chir Belg. 2010;110(2):250-254.
11. Guinot-Moya R, Valmaseda-Castellon E, Berini-Aytes L, Gay-Escoda C.
Pilomatrixoma. Review of 205 cases. Med Oral Patol Oral Cir Bucal. 2011;16
(4):e552-e555.
09/25/2019
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html
Page 13 of 14
12. Sertznig P, von Felbert V, Megahed M. Porokeratosis: Present concepts. J
Eur Acad Dermatol Venereol. 2012;26(4):404-412.
13. Spencer L. Porokeratosis. UpToDate [online serial]. Waltham, MA:
UpToDate; reviewed October 12, 2011.
14. Spencer L. Porokeratosis. eMedicine Dermatology. New York, NY: Medscape;
updated May 30, 2012.
15. American Society of Plastic Surgeons (ASPS). Practice parameters: Skin
lesions (archived) [website] Arlington Heights, IL: ASPS; March 2003.
16. Nguyen T, Zuniga R. Skin conditions: Benign nodular skin lesions. FP Essent.
2013;407:24-30.
17. Korf BR. Neurofibromatosis type 1 (NF1): Management and prognosis.
UpToDate [online serial]. Waltham, MA: UpToDate; reviewed December 2015.
18. American Academy of Family Physicians (AAFP). Common pigmentation
disorders [website]. Leawood, KS: AAFP; January 15, 2009.
19. American Academy of Family Physicians (AAFP). Treatment of nongenital
cutaneous warts [website]. Leawood, KS: AAFP; August 1, 2011.
American Cancer Society (ACS). Skin cancer prevention and early detection
[website]. Atlanta, GA: ACS; March 2015.
20. Ovejero D, Lim YH, Boyce AM, et al. Cutaneous skeletal hypophosphatemia
syndrome: Clinical spectrum, natural history, and treatment. Osteoporos Int.
2016;27(12):3615-3626.
21. Bader RS, Scarborough DA. Surgical pearl: Intralesional electrodesiccation
of sebaceous hyperplasia. JAAD. 2000;42(1):127-128.
22. North JP, McCalmont TH, Ruben BS. Cutaneous adnexal tumors. UpToDate
Inc., Waltham, MA. Last reviewed April 2019.
09/25/2019
Page 14 of 14
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan
benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial,
general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care
services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in
private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible
for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to
change.
Copyright © 2001-2019 Aetna Inc.
Proprietary
http://www.aetna.com/cpb/medical/data/600_699/0633.html 09/25/2019
AETNA BETTER HEALTH® OF PENNSYLVANIA
Amendment to Aetna Clinical Policy Bulletin Number: 0633 Benign Skin
Lesion Removal
For the Pennsylvania Medical Assistance plan, for members under the age of 21, the medical necessity of removal of visible benign skin lesions likely to affect the person’s ability to obtain future employment will be considered on a case by case basis.
www.aetnabetterhealth.com/pennsylvania revised 09/09/2019 Proprietary